Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancyDeirdre O'Mahony, John C Morris, Cate Quinn, et al.Clinical Immunology (Orlando, Fla.)|October 1, 2014
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphomaJonathan L Berkowitz, John E Janik, Donn M Stewart, et al.Blood|December 6, 2012
Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemiaThomas A Waldmann, Kevin C Conlon, Donn M Stewart, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.Beilstein Journal of Nanotechnology|June 24, 2016
Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detectionDinusha N Udukala, Hongwang Wang, Sebastian O Wendel, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaStephen J Schuster, Sattva S Neelapu, Barry L Gause, et al.Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.Pageof 14